Comparing mirikizumab vs. standard care for newly diagnosed Crohn's
Treatments studied
Part of Ear, nose & throat clinical trials.
This trial tests whether starting with a powerful biologic drug (mirikizumab) works better than the usual first treatment (azathioprine) for people who have just been diagnosed with moderate-to-severe Crohn's disease and haven't tried stronger medications yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You were diagnosed with Crohn's disease within the last year and haven't taken azathioprine, methotrexate, or any advanced biologic or small-molecule therapies.
- You have active moderate-to-severe Crohn's symptoms, with inflammation confirmed by a scope and lab tests, but no actively draining fistulas or need for urgent surgery.
- You have not had any Crohn's-related surgery or a history of cancer (except successfully treated skin cancer).
- You are willing to have an ileocolonoscopy, fill out daily diaries, and use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
Hear when a new Chrohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.